Overview

Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects

Status:
Terminated
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective - To characterize the potential pharmacokinetic interactions of artemether -lumefantrine, amodiaquine and primaquine in healthy adult subjects. Secondary Objectives - To characterize the pharmacokinetic properties of artemether-lumefantrine, amodiaquine and primaquine when given alone and in combination. - To evaluate the safety and tolerability of co-administered artemether-lumefantrine, amodiaquine and primaquine. - To investigate pharmacogenetic polymorphisms affecting drug levels of artemether-lumefantrine, amodiaquine and primaquine and their metabolites.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Oxford
Collaborators:
Mahidol Oxford Tropical Medicine Research Unit
Mahidol University
Treatments:
Amodiaquine
Artemether
Artemether-lumefantrine combination
Artemether, Lumefantrine Drug Combination
Artemisinins
Lumefantrine
Primaquine